Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Stuttgart – page 60

982 clinical trials in Stuttgart, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Stuttgart at a glance
982
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

982 trials in Stuttgart

Open in trial search

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Lung neoplasm malignant

Not recruiting

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Bladder transitional cell carcinoma

Not recruiting

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Alagille syndrome

Not recruiting

Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Stuttgart

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer, diffuse large B-cell lymphoma, and bladder cancer treatments. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Advanced Cancer Treatments
  • Immunotherapy Studies
  • Novel Drug Combinations

Several trials investigating breakthrough treatments for various forms of leukemia and solid tumors.

02 Immunology and Vaccines

Research focusing on cytomegalovirus prevention and influenza vaccination in different age groups. Studies evaluate innovative vaccine formulations and immune responses.

  • Vaccine Development
  • Immune Response Studies
  • Preventive Medicine

Trials aim to enhance vaccine efficacy and improve protection against infectious diseases.

03 Metabolic and Eye Disorders

Studies addressing weight management and various eye conditions including retinal disorders. Research includes innovative treatments for macular degeneration and vision preservation.

  • Weight Management Therapies
  • Retinal Disease Treatment
  • Vision Preservation

Focus on developing treatments that improve patient outcomes and quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.